DE69331633T2 - Arzneimittel zur hemmung der neutrophilen elastase und cathepsin g - Google Patents
Arzneimittel zur hemmung der neutrophilen elastase und cathepsin gInfo
- Publication number
- DE69331633T2 DE69331633T2 DE69331633T DE69331633T DE69331633T2 DE 69331633 T2 DE69331633 T2 DE 69331633T2 DE 69331633 T DE69331633 T DE 69331633T DE 69331633 T DE69331633 T DE 69331633T DE 69331633 T2 DE69331633 T2 DE 69331633T2
- Authority
- DE
- Germany
- Prior art keywords
- cathepsin
- desulfated heparin
- inhibiting
- medicament
- medicinal products
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 102000016387 Pancreatic elastase Human genes 0.000 title abstract 2
- 108010067372 Pancreatic elastase Proteins 0.000 title abstract 2
- 102000005600 Cathepsins Human genes 0.000 title 1
- 108010084457 Cathepsins Proteins 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 229940126601 medicinal product Drugs 0.000 title 1
- 230000003448 neutrophilic effect Effects 0.000 title 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 4
- 239000003814 drug Substances 0.000 abstract 3
- LKDMKWNDBAVNQZ-UHFFFAOYSA-N 4-[[1-[[1-[2-[[1-(4-nitroanilino)-1-oxo-3-phenylpropan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)NC(C)C(=O)NC(C)C(=O)N1CCCC1C(=O)NC(C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)CC1=CC=CC=C1 LKDMKWNDBAVNQZ-UHFFFAOYSA-N 0.000 abstract 2
- 102000004173 Cathepsin G Human genes 0.000 abstract 2
- 108090000617 Cathepsin G Proteins 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 2
- 238000001990 intravenous administration Methods 0.000 abstract 2
- 108010028275 Leukocyte Elastase Proteins 0.000 abstract 1
- 102000016799 Leukocyte elastase Human genes 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 238000012387 aerosolization Methods 0.000 abstract 1
- 239000007975 buffered saline Substances 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000002347 injection Methods 0.000 abstract 1
- 239000007924 injection Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Materials Engineering (AREA)
- Pain & Pain Management (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Polymers & Plastics (AREA)
- Vascular Medicine (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- External Artificial Organs (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Orthopedics, Nursing, And Contraception (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91930992A | 1992-07-24 | 1992-07-24 | |
| PCT/US1993/006933 WO1994002107A2 (en) | 1992-07-24 | 1993-07-23 | Method and medicament for inhibiting neutrophil elastase and cathepsin g |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69331633D1 DE69331633D1 (de) | 2002-04-04 |
| DE69331633T2 true DE69331633T2 (de) | 2002-10-31 |
Family
ID=25441870
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69334190T Expired - Fee Related DE69334190T2 (de) | 1992-07-24 | 1993-07-23 | Nicht-antikoagulierende desulfatierte Heparine als Medikamente |
| DE69331633T Expired - Fee Related DE69331633T2 (de) | 1992-07-24 | 1993-07-23 | Arzneimittel zur hemmung der neutrophilen elastase und cathepsin g |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69334190T Expired - Fee Related DE69334190T2 (de) | 1992-07-24 | 1993-07-23 | Nicht-antikoagulierende desulfatierte Heparine als Medikamente |
Country Status (10)
| Country | Link |
|---|---|
| EP (2) | EP1164145B1 (de) |
| JP (1) | JPH08511764A (de) |
| AT (2) | ATE380047T1 (de) |
| AU (1) | AU688272B2 (de) |
| CA (1) | CA2140890C (de) |
| DE (2) | DE69334190T2 (de) |
| DK (2) | DK0651645T3 (de) |
| ES (2) | ES2173893T3 (de) |
| PT (1) | PT1164145E (de) |
| WO (1) | WO1994002107A2 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| AU6246394A (en) * | 1993-02-22 | 1994-09-14 | Cavalier Pharmaceuticals, Inc. | Use of heparin to inhibit interleukin-8 |
| US6242414B1 (en) | 1995-06-07 | 2001-06-05 | Chiron Corporation | Regulation of cytokine synthesis and release |
| WO2002032406A2 (en) * | 2000-10-18 | 2002-04-25 | Massachusetts Institute Of Technology | Methods and products related to pulmonary delivery of polysaccharides |
| GB0327723D0 (en) * | 2003-09-15 | 2003-12-31 | Vectura Ltd | Pharmaceutical compositions |
| US7468358B2 (en) * | 2004-06-16 | 2008-12-23 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2584606A1 (fr) * | 1985-07-12 | 1987-01-16 | Dropic | Utilisation de poly- et oligosaccharides pour l'obtention de medicaments actifs dans les pathologies du tissu conjonctif |
| US5262403A (en) * | 1986-03-10 | 1993-11-16 | Board Of Regents, The University Of Texas System | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness of metastatic profusion-II |
| AU7852687A (en) * | 1986-08-21 | 1988-03-08 | University Of Texas System, The | Glycosaminoglycan derivatives and their use as inhibitors of tumor invasiveness or metastatic profusion |
| IT1254216B (it) * | 1992-02-25 | 1995-09-14 | Opocrin Spa | Derivati polisaccaridici di eparina, eparan solfato, loro frazioni e frammenti, procedimento per la loro preparazione e composizioni farmaceutiche che li contengono |
-
1993
- 1993-07-23 DE DE69334190T patent/DE69334190T2/de not_active Expired - Fee Related
- 1993-07-23 ES ES93918338T patent/ES2173893T3/es not_active Expired - Lifetime
- 1993-07-23 DE DE69331633T patent/DE69331633T2/de not_active Expired - Fee Related
- 1993-07-23 AT AT01115601T patent/ATE380047T1/de not_active IP Right Cessation
- 1993-07-23 ES ES01115601T patent/ES2295087T3/es not_active Expired - Lifetime
- 1993-07-23 EP EP01115601A patent/EP1164145B1/de not_active Expired - Lifetime
- 1993-07-23 AU AU47824/93A patent/AU688272B2/en not_active Ceased
- 1993-07-23 CA CA002140890A patent/CA2140890C/en not_active Expired - Fee Related
- 1993-07-23 DK DK93918338T patent/DK0651645T3/da active
- 1993-07-23 DK DK01115601T patent/DK1164145T3/da active
- 1993-07-23 EP EP93918338A patent/EP0651645B1/de not_active Expired - Lifetime
- 1993-07-23 AT AT93918338T patent/ATE213636T1/de not_active IP Right Cessation
- 1993-07-23 PT PT01115601T patent/PT1164145E/pt unknown
- 1993-07-23 JP JP6504708A patent/JPH08511764A/ja not_active Withdrawn
- 1993-07-23 WO PCT/US1993/006933 patent/WO1994002107A2/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| ES2173893T3 (es) | 2002-11-01 |
| ES2295087T3 (es) | 2008-04-16 |
| PT1164145E (pt) | 2008-03-17 |
| WO1994002107A2 (en) | 1994-02-03 |
| DE69334190T2 (de) | 2008-11-27 |
| DE69334190D1 (de) | 2008-01-17 |
| EP1164145A3 (de) | 2002-01-30 |
| DK0651645T3 (da) | 2002-06-10 |
| JPH08511764A (ja) | 1996-12-10 |
| AU4782493A (en) | 1994-02-14 |
| ATE213636T1 (de) | 2002-03-15 |
| DK1164145T3 (da) | 2008-04-14 |
| ATE380047T1 (de) | 2007-12-15 |
| EP0651645A1 (de) | 1995-05-10 |
| EP1164145B1 (de) | 2007-12-05 |
| CA2140890A1 (en) | 1994-02-03 |
| EP1164145A2 (de) | 2001-12-19 |
| WO1994002107A3 (en) | 1994-05-11 |
| CA2140890C (en) | 2003-10-07 |
| EP0651645B1 (de) | 2002-02-27 |
| DE69331633D1 (de) | 2002-04-04 |
| AU688272B2 (en) | 1998-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2137948T3 (es) | Sistema avanzado de administracion de medicamentos y metodo de tratamiento de trastornos psiquiatricos, neurologicos y otros con carbamacepina. | |
| ATE196089T1 (de) | Mittel zur hemmung des komplementsystems hergestellt aus fucanen aus braunen algen | |
| BR9205640A (pt) | Dímero de apolipoproteína ai-milano, composiçao farmacológica, processo de preparaçao do dímero, uso deste na preparaçao de medicamentos e processo para o tratamento de aterosclerose e doenças cardiovasculares | |
| KR930702022A (ko) | 인슐린의 경구 투여에 의한 타잎 1 당뇨병의 치료 또는 예방법 | |
| ATE240344T1 (de) | Nor-pregnane zur induzierung hypothalamischer effekte | |
| BR0213293A (pt) | Uso de tfpi ou de um análogo de tfpi no tratamento de septicemia | |
| DE69331633T2 (de) | Arzneimittel zur hemmung der neutrophilen elastase und cathepsin g | |
| PT666739E (pt) | Solucao intravenosa que diminui a perda de proteina no corpo. | |
| ZA90600B (en) | Treatment of leukocyte dysefunction with gm-csf | |
| KR960705578A (ko) | 경증 질환을 가진 b형 간염 보균자의 치료방법(method for treating hepatitis b carriers with minimal disease) | |
| CA2159485A1 (en) | Anti-oxydant alkylaryl polyether alcohol polymers | |
| CA2140010A1 (en) | Blood coagulation normalizer containing tcf-ii as active ingredient | |
| NO960545D0 (no) | Behandling av skadelige virkninger i forbindelse med administrering av ekstracellulært hemoglobin | |
| DE68910010D1 (de) | Verwendung von Dapiprazol zur Herstellung eines Arzneimittels zur Verhinderung des Toleranzentwicklung bei der analgetischen Behandlung mit Morphin. | |
| MX9801538A (es) | Metodos y composiciones para el tratamiento de infecciones fungales en mamiferos. | |
| FR2701213B3 (fr) | Canule d'injection pour traitements médicaux. | |
| PT84619A (de) | 2,4,6-tris-tertiaerbutylamino-1,3,5-triazin zur prophylaxe und behandlung von epilepsie und angstzustaenden verwendung dieser verbindung zur herstellung eines arzneimittels sowie arzneimittel auf basis dieser verbindung | |
| TH19834EX (th) | วิธีการรักษาเซฟติคซอคโดยใช้ไธโมซิน-อัลฟา1 | |
| ATE280584T1 (de) | Verwendung von beta interferon zur herstellung eines arzneimittels zur behandlung von ewings sarkom und eoe | |
| KR930700109A (ko) | 신경 질환 치료용 4,4'-[9h-플루오렌-9-일리덴비스(메틸렌)]-비스피리미딘 | |
| RU99111088A (ru) | Способ лечения инфекции streptococcus pneumoniae | |
| RU97105771A (ru) | Способ лечения сахарного диабета | |
| TH19834A (th) | วิธีการรักษาเซฟติคซอคโดยใช้ไธโมซิน-อัลฟา1 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8327 | Change in the person/name/address of the patent owner |
Owner name: PARINGENIX,INC.,, WESTON, FLA., US |
|
| 8381 | Inventor (new situation) |
Inventor name: KENNEDY, THOMAS P., RICHMOND, US |
|
| 8339 | Ceased/non-payment of the annual fee |